Overview

A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor

Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy of SAGE-324 compared to placebo on upper limb tremor reduction in individuals with essential tremor (ET).
Phase:
Phase 2
Details
Lead Sponsor:
Sage Therapeutics